Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Accumulated Expenses (2022 - 2025)

Gossamer Bio (GOSS) has 3 years of Accumulated Expenses data on record, last reported at $10.5 million in Q4 2024.

  • For Q4 2024, Accumulated Expenses rose 34.4% year-over-year to $10.5 million; the TTM value through Dec 2024 reached $10.5 million, up 34.4%, while the annual FY2024 figure was $10.5 million, 34.4% up from the prior year.
  • Accumulated Expenses reached $10.5 million in Q4 2024 per GOSS's latest filing, down from $17.4 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $20.7 million in Q3 2022 and bottomed at $7.8 million in Q4 2023.
  • Average Accumulated Expenses over 3 years is $14.5 million, with a median of $15.2 million recorded in 2022.
  • Peak YoY movement for Accumulated Expenses: crashed 50.22% in 2023, then surged 34.4% in 2024.
  • A 3-year view of Accumulated Expenses shows it stood at $15.6 million in 2022, then plummeted by 50.22% to $7.8 million in 2023, then soared by 34.4% to $10.5 million in 2024.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $10.5 million in Q4 2024, $17.4 million in Q3 2024, and $7.8 million in Q4 2023.